在PETHEMA试验中治疗的成人T细胞急性淋巴细胞白血病患者的遗传演变和复发相关突变
Celia González-Gil1, Thaysa Lopes1, Mireia Morgades2
1Institut d'Investigació contra la Leucemia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol Universitat Autònoma de Barcelona Badalona Spain.
HemaSphere
|May 27, 2025
概括
成年T细胞急性淋巴细胞白血病 (T-ALL) 的复发是由特定的遗传突变驱动的. 在诊断时识别这些标志物可以预测早期或晚期复发,改善T-ALL患者的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 复发是成年T细胞急性淋巴细胞白血病 (T-ALL) 治疗失败的主要原因.
- 对于接受特定化疗的成年T-ALL患者的预测标志物和复发机制的数据有限.
- 了解复发的遗传驱动因素对于改善结果至关重要.
研究的目的:
- 确定与成人T-ALL复发相关的遗传决定因素.
- 分析成年T-ALL患者的对诊断-复发样本,这些患者在可测量的残留疾病导向试验中接受治疗.
- 区分与早期与晚期复发相关的遗传特征.
主要方法:
- 从37名成年T-ALL患者的74个对诊断-复发样本中分析单核酸变异和副本数量变化.
- 传统的分子技术和单细胞分析.
- 数字PCR用于跟踪特定的遗传变异,如NT5C2.2.
主要成果:
- 在诊断时发现了N/KRAS突变,在20%的病例中复发,与巩固期间的早期复发相关.
- 在40%的复发病例中发现了复发特异性突变 (NT5C2,NR3C1,SMARCA4,TP53),通常在常规方法诊断时无法检测到.
- 单细胞分析显示,诊断时具有NT5C2变异的小克隆,在维持治疗期间与以后的复发相关.
- 这些遗传事件导致大约60%的成年T-ALL患者复发.
结论:
- 在诊断时的N/KRAS突变预测成人T-ALL的早期复发.
- 不同的遗传特征,包括NT5C2变异,与晚期复发有关,可能源于诊断时存在的小克隆.
- 这些发现强调了全面基因分析对于理解和预测成人T-ALL.复发的重要性.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K